Objective: This study aimed to determine the risk factors for intra-abdominal infections (IAIs), assess the clinical outcomes of IAIs, and investigate the spectrum and antimicrobial resistance of major pathogens causing IAIs. Results: A total of 2,756 patients were included. The 30-day all-cause mortality was 9.5% (262/2,756). Multivariable analysis showed that the following independent risk factors were associated with the 30-day mortality: age >60 years, pulmonary disease, tracheal cannula, infection occurring in intensive care unit (ICU), prior admission within 3 months, antibiotic use before infection, recent use of immunosuppressants, and multidrug-resistant organisms. In addition, 2,913 clinical isolates were collected. The Gram-negative and Gram-positive bacteria accounted for 70.8% and 29.2% of all isolates, respectively. The most common pathogens were Escherichia coli (33.4%), Klebsiella pneumoniae (10.8%), and Enterococcus faecium (10.7%). Pseudomonas aeruginosa and Acinetobacter baumannii were the most common non-Enterobacteriaceae Gram-negative pathogens. E. faecium, Enterococcus faecalis, and Staphylococcus aureus were the most common Gram-positive pathogens. E. coli, A. baumannii, and Enterobacter cloacae were more commonly found in ICU patients than in non-ICU patients. Overall, the antibiotics tested in the CARES exhibited diminished susceptibility to pathogens over the study period, especially extended spectrum β-lactamase producing isolates. Conclusion: Considering the current data set and high-level resistance of intra-abdominal pathogens to various antibiotics, further monitoring of the epidemiology of IAIs and their susceptibility to antibiotics through the CARES is warranted.
Introduction
The 
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Zhang et al gens in nosocomial infections in China. This nationwide surveillance program focuses on nosocomial infections, including bloodstream infections, hospital-acquired pneumonia, and intra-abdominal infections (IAIs), and currently includes 15 tertiary care hospitals.
IAIs are frequently encountered in clinical practice in hospital and healthcare settings. The etiology of these infections, usually polymicrobial in nature, can be diverse and often involves microorganisms derived from the intestinal microbiota. 1 IAIs are the second most common cause of infectious mortality in intensive care units (ICUs) and commonly result in high mortality and morbidity rates. 2, 3 This study aimed to investigate the prevalence, risk factors, and outcomes of nosocomial IAIs in patients admitted to 15 Chinese teaching hospitals involved in the CARES between 2007 and 2016.
Patients and methods study centers and patients
A total of 15 study centers were included in the CARES, and this prospective observational study enrolled 2,756 patients with nosocomial IAIs from the CARES program between 2007 and 2016. The criteria for IAI diagnosis were as follows: 1. Presence of organisms cultured from purulent material sampled from the intra-abdominal space during surgical operation or needle aspiration. 2. Presence of abscess or other evidence of IAI observed during surgical operation or histopathologic examination. 3. Presence of at least two of the following signs or symptoms with no other recognized cause: fever (>38°C), nausea, vomiting, abdominal pain, or jaundice. In addition, at least one of the following criteria is matched: a. Organisms cultured from drainage of a surgically placed drain (such as closed-suction drainage system, open drain, or T-tube drain). b. Organisms observed on Gram's stain of drainage or tissue obtained during surgical operation or needle aspiration. c. Organisms cultured from blood and radiographic evidence of infection (eg, abnormal findings on ultrasound, computed tomography, magnetic resonance imaging, radiolabel scans, or abdominal X-ray radiographs). 4 According to the Infectious Diseases Society of America guideline, nosocomial infection includes cases involving patients with positive culture results from a normally sterile site obtained >48 hours after hospital admission. 5 This study aimed to investigate the nosocomial IAIs, so patients with positive culture results from intra-abdominal body sites obtained ≤48 hours after admission were excluded. Then all patients enrolled in this study were considered as nosocomial IAIs. Patients with incomplete data were also excluded. All data included were confirmed by chart review.
Bacterial isolates
All isolates were collected from 15 tertiary care hospitals and cultured from specimens obtained from intra-abdominal body sites (eg, appendix, peritoneum, colon, bile, pelvis, or pancreas). 6, 7 Acceptable specimens included tissue, fluid, or deep wound cultures obtained intra-operatively as well as fluid from paracentesis or percutaneous aspiration of abscesses. 8, 9 Isolates recovered from blood, urine, and perirectal abscess sources outside the intra-abdominal body sites were excluded. 3 antimicrobial susceptibility testing Antimicrobial susceptibility was determined by the agar dilution method and broth microdilution method (only for tigecycline), and the results were interpreted according to the minimum inhibitory concentration (MIC) interpretive breakpoints recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2017. 10 The tested antimicrobial agents included amikacin, ampicillin, ceftazidime, chloramphenicol, cefotaxime, erythromycin, cefepime, cefoxitin, levofloxacin, moxifloxacin, minocycline, rifampicin, sulfamethoxazole, teicoplanin, vancomycin (National Institute for Food and Drug Control of China, Beijing, China), ciprofloxacin (Bayer AG, Leverkusen, Germany), ceftriaxone (Hoffman-La Roche Ltd., Basel, Switzerland), cefoperazone/sulbactam, piperacillin/tazobactam, tigecycline (Pfizer, Inc., New York, NY, USA), imipenem (Merck & Co., Inc., Whitehouse Station, NJ, USA), and meropenem (Sumitomo Dainippon Pharma, Osaka, Japan). The tigecycline test was performed according to the Food and Drug Administration standards. The doubledisk synergy test was used to determine extended spectrum β-lactamase (ESBL) production among isolates of Escherichia coli and Klebsiella pneumoniae as recommended by the CLSI. 10 The reference isolates E. faecalis ATCC 29212, S. aureus ATCC29213, E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as quality control isolates.
statistical analyses
The chi-squared test or Fisher's exact test was used to compare the categorical variables, and Student's t-test was used to compare the continuous variables. To control the effects of confounding variables and identify the independent risk factors associated with death, a stepwise conditional logistic regression analysis was performed. 11 All variables with a P-value <0.10 
Ethical statement
This study was approved by the research ethics board at Peking University People's Hospital. Informed consent was not needed due to that the medical records and patient information were anonymously reviewed and collected in this observational study.
Results

Baseline data
A total of 2,756 patients were included in this study: 2,494 patients (90.5%) in the survival group and 262 patients (9.5%) in the nonsurvival group. In the survival group, the median age was 57 years (range, 1-94 years) and 1,509 (60.5%) of them were men. In the nonsurvival group, the median age was 62 years (range, 1-92 years) and 150 (57.3%) of them were men. The 30-day all-cause mortality was 9.5% (262/2756). The main demographic and clinical features of all patients are summarized in Table 1 .
species distribution of isolates
A total of 2,913 clinical isolates were collected from intraabdominal body sites. The species distribution of these isolates is listed in Table 2 . Gram-negative bacteria accounted for 70.8% and Gram-positive bacteria accounted for 29.2% of the isolates. The most common species were E. coli (973, 33.4%), K. pneumoniae (314, 10.8%), and Enterococcus faecium (312, 10.7%), followed by P. aeruginosa (230, 7.9%), Acinetobacter baumannii (186, 6.4%), Enterococcus faecalis (175, 6.0%), Staphylococcus aureus (140, 4.8%), and Enterobacter cloacae (104, 3.6%).
The species distribution of microorganisms collected from patients hospitalized in the ICU and non-ICU wards is presented in Table 3 (only species with ≥40 isolates are listed). E. coli, A. baumannii, and E. cloacae were more commonly found in ICU patients than in non-ICU patients (P<0.001, P<0.001, and P=0.018, respectively).
Risk factors associated with the 30-day mortality
The results for the stepwise conditional logistic regression analysis of the multiple risk factors associated with death are presented in 
E. coli
A total of 973 isolates were collected, including 491 ESBLpositive isolates and 482 ESBL-negative isolates. For these isolates, meropenem, imipenem, and tigecycline showed the highest activity (all ≥97.8% susceptible) against E. coli. However, some antibiotics exhibited very poor potency. Notably, ceftriaxone and cefotaxime were the least active agents, only displaying 0.8% susceptibility against ESBLpositive isolates. In addition, there was a relatively smooth uptrend of ESBL-producing E. coli isolates from 47.4% in 2007 to 52.7% in 2016.
K. pneumoniae
A total of 314 isolates were collected, including 77 ESBLpositive isolates and 237 ESBL-negative isolates. Meropenem, imipenem, and tigecycline showed highest activity (all ≥92.0% susceptible) against K. pneumoniae. In addition, there was a relatively smooth uptrend of ESBL-producing K. pneumoniae isolates between 2007 and 2016 (except in 2011). Both P. aeruginosa and A. baumannii showed the same trend of an initial increase followed by a decrease in resistance to carbapenems. Nonetheless, a high resistance to carbapenems was a big threat with both the organisms.
P. aeruginosa and A. baumannii
S. aureus
A total of 140 S. aureus isolates were collected, including 89 methicillin-susceptible S. aureus (MSSA) isolates (63.6%) and 51 methicillin-resistant S. aureus (MRSA) isolates (36.4%). All these isolates were susceptible to teicoplanin and vancomycin. In addition, all MSSA isolates were susceptible to minocycline. In contrast, fluoroquinolones (ciprofloxacin, levofloxacin, and moxifloxacin) exhibited very poor activity against MRSA isolates. Erythromycin exhibited poor activity against both MRSA (13.8% susceptible) and MSSA (37.2% susceptible) isolates. The MRSA isolates showed an increasing trend from 2011 to 2016.
E. faecalis and E. faecium
A total of 175 E. faecalis and 312 E. faecium isolates were collected. All the isolates were susceptible to teicoplanin and vancomycin (≥97.4% susceptible). Overall, E. faecium isolates had a high resistance (84.0% resistant) to ampicillin, whereas E. faecalis isolates were much more susceptible to ampicillin (93.5% susceptible). Only 1.9% of E. faecium isolates showed resistance to vancomycin with a decreasing trend in resistance between 2007 and 2016.
Discussion
In this study, we investigated the risk factors for nosocomial IAIs and the outcomes of these infections. We found that age >60 years, pulmonary disease, tracheal cannula, infection occurring in ICU, prior admission within 3 months, antibiotics use before infection, recent use of immunosuppressants, and multidrug-resistant organisms were independent predic- tors of patient survival. Compared to other representative surveillance programs which monitor the epidemiology and trends in antibiotic resistance of intra-abdominal pathogens to currently used therapies, such as the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, this study collected the demographic and clinical data of the patients in detail and analyzed the risk factors and clinical outcomes of nosocomial IAIs in China. The data and results of this study may be helpful to the IAI treatment in clinic. A total of 2,913 isolates were collected from 15 tertiary care teaching hospitals involved in the CARES between 2007 and 2016. We analyzed the updated epidemiology and antimicrobial susceptibility of the causative pathogens. The epidemiological data from our study highlights the diversity of intra-abdominal pathogens, as many different species causing IAIs were isolated. Of these, the most common species were E. coli (33.4%), K. pneumoniae (10.8%), and E. faecium (10.7%). Not surprisingly, Enterobacteriaceae isolates were the predominant species causing IAIs, accounting for at least 50% of all isolated pathogens.
Our study using data from the CARES program revealed several important findings. First, the combinations of cephalosporins, fluoroquinolones, and β-lactam/β-lactamase inhibitors tested in the CARES exhibited diminished susceptibility against the collected isolates over the study period. Second, the nonfermentative Gram-negative 
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epidemiology data analyses of intra-abdominal infections in the caRes bacilli were alarmingly resistant to diverse classes of antimicrobial agents. The susceptibilities of A. baumannii isolates to carbapenems, third-or fourth-generation cephalosporins, fluoroquinolones, and aminoglycosides were less than ~30%, which presents a key problem for empirical therapeutic choice. Although A. baumannii was not a major pathogen for IAIs, the trends of its resistance, especially, to carbapenems should be monitored. 13 Third, amikacin, tigecycline, and carbapenems including imipenem and meropenem were consistently potent against Enterobacteriaceae isolates throughout the study period. Thus, tigecycline monotherapy, carbapenem monotherapy, or amikacin-based combination therapy could provide the strongest activity against Enterobacteriaceae causing IAIs. 8 Fourth, the overall increase in the isolation of Gram-positive pathogens was accompanied by an increase in the multidrug-resistant phenotypes, making it difficult to choose the appropriate therapy for IAIs.
In our study, ESBL-producing isolates showed high-level resistance to diverse antimicrobial agents. A high prevalence of ESBL-producing isolates in China has been reported in several studies, and the continually diminishing susceptibility to many antimicrobial agents is alarming. 6, 14 The SMART study, which monitored the resistance of Gram-negative pathogens causing IAIs, showed that 43.9% of E. coli and 30.4% of K. pneumoniae isolates were ESBL producers. 3 These ESBL-producing strains exhibited resistance to more antibiotics than non-ESBL-producing strains. Our current study showed that carbapenems and amikacin are the most active antibiotics, which was consistent with our antimicrobial susceptibility results. So far, the recommended antibiotics for the treatment of serious infections caused by ESBL-producing bacteria are carbapenems, particularly for patients with severe sepsis. 15 A previous study showed that the adequacy of initial antibiotic therapy for serious ESBLinfection was associated with mortality. 16 A steady decrease in the susceptibility to most noncarbapenem antimicrobial agents has been observed over time; however, the carbapenem consumption has increased and maybe the reason for the increasing carbapenem resistance reported among Enterobacteriaceae species. 17 Despite increased consumption of carbapenems and the emergence of varieties of carbapenem resistant mechanisms, susceptibility of Enterobacteriaceae species to carbapenems was consistently high in our study.
Infections caused by resistant microorganisms increase the risk of mortality, especially because the initial empiric therapy may be inadequate. 1 Due to the dissimilarity in the nature of the IAI pathogens, appropriate antibiotics for IAIs were studied, leading to differences in antibiotic treatment. Two publications were recommended as guidelines for empirical antibiotic treatment for IAIs. 18, 19 To select adequate therapy for IAIs in clinical practice, updated data on the local resistance epidemiology of these pathogens should be available; 1 therefore, surveillance studies are necessary. Many epidemiological surveillance programs and studies worldwide, such as the SMART, China antimicrobial Surveillance Network (http://www.chinets. com), and CARES, have provided important information on the pathogens involved in many infections and ongoing resistance to the main classes of antibiotics used in clinical practice. Surveillance studies are key in not only identifying specific pathogens associated with IAIs but also assessing resistance rates and trends in resistance for antimicrobials commonly used to treat IAIs. The combination of resistance rates, trends in resistance over time, and trends in mechanisms of resistance will help physicians, pharmacists, and clinical microbiologists understand the evolution and spread of pathogens. 20 Despite our important findings, the main problem of the present study is that it is observational in nature, which might result in limitations that preclude accurate comparisons, and thus unknown risk factors might have been unequally distributed between groups.
Conclusion
Antibiotic resistance among IAI-causing species is a serious threat in China, and close monitoring of antibiotic resistance among pathogens associated with IAIs is crucial for guiding measures to prevent further emergence of resistance and to provide clinicians with the necessary information to appropriately select empirical therapy. Up-to-date national, regional, and global microbial surveillance is needed to provide updated information for the optimal therapy of IAIs.
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